FIELD: medicine.
SUBSTANCE: invention represents a pharmaceutical composition for treating epithelioma in a human where said pharmaceutical composition contains a bispecific single-chained antibody exhibiting a first binding domain specifically bound with human CD3, and a second binding domain specifically bound with human CEA. Besides, there are described methods of preparing said pharmaceutical composition, a method and a kit for preventing, treating or relieving epithelioma.
EFFECT: invention can be effectively used for treating epithelioma.
28 cl, 27 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| BISPECIFIC SINGLE-CHAIN ANTIBODY TO PSMAxCD3 WITH INTERSPECIES SPECIFICITY | 2011 |
|
RU2617942C2 |
| PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| CD3-EPSILON-BINDING DOMAIN HAVING INTERSPECIES SPECIFICITY | 2008 |
|
RU2561457C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
